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Abstract
Background: Addiction, overdoses and deaths resulting from prescription opioids have increased dramatically over
the last decade. In response, several manufacturers have developed formulations of opioids with abuse-deterrent
properties. For many of these products, the Food and Drug Administration (FDA) recognized the formulation with
labeling claims and mandated post-marketing studies to assess the abuse-deterrent effects. In response, we assess
differences in rates of opioid-related overdoses and poisonings prior to and following the introduction of a
formulation of OxyContin® with abuse-deterrent properties.
Methods/Design: To assess effects of this formulation, electronic medical record (EMR) data from Kaiser Permanente
Northwest (KPNW) and Kaiser Permanente Northern California (KPNC) are linked to state death data and compared to
chart audits. Overdose and poisoning events will be categorized by intentionality and number of agents involved,
including illicit drugs and alcohol. Using 6-month intervals over a 10-year period, trends will be compared in rates of
opioid-related overdoses and poisoning events associated with OxyContin® to rates of events associated with other
oxycodone and opioid formulations. Qualitative interviews with patients and relatives of deceased patients will be
conducted to capture circumstances surrounding events.
Discussion: This study assesses and tracks changes in opioid-related overdoses and poisoning events prior to and
following the introduction of OxyContin® with abuse-deterrent properties. Public health significance is high because
these medications are designed to reduce abuse-related behaviors that lead to important adverse outcomes, including
overdoses and deaths.
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Background
As opioid-related risks to public health have become
apparent [1–9] various efforts have been implemented to
mitigate opioid-related negative outcomes. States have
implemented prescription drug monitoring programs
[10, 11], and the FDA now requires manufacturers of
long-acting opioids to develop Risk Evaluation and
Mitigation Strategies (REMS) and encourages opioid
prescribers to complete REMS-compliant education pro-
grams [12]. Manufacturers of long-acting opioids have
also begun reformulating products to include abuse-
deterrent properties, with the goal of reducing prescrip-
tion opioid abuse [13]. In April 2010, the FDA approved
a reformulation of OxyContin® (manufactured by Purdue
Pharma L.P.) with abuse-deterrent properties. The goal
of the abuse-deterrent formulation was to make it
difficult to crush, cut, break or liquefy pills, reducing
likelihood that the medication could be snorted, smoked,
* Correspondence: Shannon.L.Janoff@kpchr.org
1Center for Health Research, Kaiser Permanente Northwest, 3800 N. Interstate
Avenue, Portland, OR 97227, USA
Full list of author information is available at the end of the article
© 2016 Janoff et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Janoff et al. BMC Pharmacology and Toxicology  (2016) 17:21 
DOI 10.1186/s40360-016-0064-y
or injected. The reformulated product was introduced to
the market in August 2010. In April 2013, the FDA ap-
proved labeling claims that OxyContin® was expected to
result in “reduced abuse through intranasal and injecting
routes” [14], although abuse by these methods, and the
oral route, is still possible [15]. Evidence since its intro-
duction shows that rates of abuse have diminished [16, 17]
and then leveled off [15], as have overdoses attributed to
prescription opioids [18]. Calls to poison centers related
to OxyContin® abuse, accidental exposures, and thera-
peutic errors were similarly reduced [19, 20]. In contrast,
heroin use and heroin overdoses have increased substan-
tially in recent years [18, 21], attributable to the prescrip-
tion drug epidemic [22] and, in part, to switching from
abuse-deterrent opioid formulations to heroin [23]. No
harms or adverse effects have been identified related to
the physical/chemical properties of the reformulated
medication when it is abused, though such harms have
been documented in the case of other medications,
including injection of temazepam gel capsules [24], and
thrombotic thrombocytopenia purpura resulting from
injection of abuse-deterrent extended-release Opana [25].
Despite this evidence, a comprehensive assessment of the
effects of abuse-deterrent OxyContin® on overdose is lack-
ing. The study protocol described here is a mixed methods
research project designed to address that gap by using full
electronic medical records of two large integrated health
plans, linked to state death data, and to interviews with
individuals experiencing overdoses, or their family mem-
bers. We analyze overdose rates among individuals with
active opioid prescriptions, classified in groups, and among
individuals without opioid prescriptions. We also examine
changes in heroin-related overdoses. Analyses are based on
patient electronic medical record (EMR) data, chart audits,
and in-depth qualitative interviews.
Methods
Study design
This mixed methods study is designed to compare rates
of overdose and poisoning events before and after the
August 2010 introduction of the abuse-deterrent formu-
lation of OxyContin®. It is one of a series of post-
marketing research protocols required by the FDA and
funded by Purdue Pharma L.P., the manufacturer of
OxyContin®. The primary specific aims of the study
are to:
1) Assess the validity of International Classification of
Diseases (ICD-9 and ICD-10) diagnoses to accurately
identify and categorize opioid-related overdoses and
poisonings using chart audits.
2) Estimate rates of, and compare trends in,
opioid-related overdoses among all members
of the participating health plans:
a. before and after the introduction of OxyContin®
with abuse-deterrent properties,
b. among patients with and without active opioid
prescriptions,
3) Compare the ratio of rates of opioid-related
overdoses and poisoning events among patients
prescribed and dispensed OxyContin® with rates in
comparator opioid groups, 2 years prior to and
2 years following the introduction of the new
formulation of OxyContin®.
4) Conduct exploratory in-depth interviews with a
subset of patients who experience opioid-related
overdoses and poisoning events (or their relatives) to
examine and understand circumstances surrounding
overdose events, and involvement of OxyContin®.
Triangulate data with chart audit data to describe
substances involved in overdoses, including heroin,
and assess whether individuals abusing OxyContin®
switch to heroin in response to the new formulation.
Setting
The setting for this study is Kaiser Permanente Northwest
(KPNW) and Kaiser Permanente Northern California
(KPNC), nonprofit, group model, integrated health sys-
tems serving about 3.9 million members (500,000 in
KPNW and 3.4 million in KPNC). KPNW and KPNC pro-
vide outpatient and inpatient medical, mental health, and
addiction treatment services and they maintain integrated
EMRs that contain comprehensive administrative and
treatment data on all members. Though the majority of
the membership in both health plans is comprised of indi-
viduals with private insurance, both plans cover substan-
tial numbers of Medicare members and, to a lessor extent,
Medicaid members. Consistent with other settings, sub-
stance abuse and misuse are common, and the health
plans’ membership is generally representative of the popu-
lations in the geographic areas they serve. The study
protocol and all study procedures are reviewed, approved,
and monitored by the Research Subjects Protection Office
of the Institutional Review Board at KPNW.
Population
The study population includes all members of the KPNW
and KPNC health systems from February 1, 2003 through
July 1, 2013. The total sample size will include approxi-
mately 7,500,000 unique individuals across the two health
plans (~1,100,000 from KPNW and ~6,400,000 from
KPNC).
Aims 1–3: quantitative data collection
Opioid-related overdoses and poisoning event
identification and categorization
Overdoses and poisonings are identified through ICD-9
and ICD-10 codes in EMRs and state death records, and
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linked to clinical and administrative data, including
pharmacy dispense records (including medication dis-
pensed, dose and days supply), inpatient and outpatient
records, and insurance claims for services received out-
side the health plans (e.g., emergency department visits
to non-health plan hospitals). Dispense records are avail-
able for nearly all health plan members, and dose and
days supply are used to calculate morphine equivalents
[26] for each individual included in analyses. Cases are
defined as poisonings (Case 1; see Table 1) or overdoses
(Case 2; see Table 2) using diagnosis and cause-of-death
codes. When multiple events occur for a given person,
events on sequential days are considered the same event
and events on non-sequential days are considered
unique. Death data from Washington, Oregon, and
California are incorporated to capture additional opioid-
related overdoses and poisoning events that may have
resulted in deaths not captured in the KPNW or KPNC
EMR systems.
Opioid-related overdoses and poisoning events are
linked to pharmacy dispense records to determine which
opioid(s), if any, are active at the time of the event. Since
patients on opioid therapy may receive more than one
active opioid (e.g., one sustained-release opioid for
chronic pain and another short-acting opioid to be used
as needed for breakthrough pain), we group and
categorize opioids in a hierarchical structure to allow for
only one active opioid medication category to be associ-
ated with any identified opioid-related overdose or poi-
soning event. Information about additional involved
medications, illicit drugs, and alcohol are also collected.
Because we are most interested in trends following the
introduction of OxyContin® with abuse-deterrent prop-
erties, for comparison purposes, we classify opioid
medications using a hierarchy with OxyContin® (includ-
ing generic single ingredient sustained-release oxy-
codone) at the top level, followed by single-ingredient
immediate release oxycodone, then other class REMS
opioids, other opioids (including multiple ingredient im-
mediate release opioids), and no opioids (i.e., no phar-
macy record indicating an active opioid prescription at
the time of the event). It the latter case, opioid over-
doses are considered indications of illicit use. Table 3
details this classification structure and the information
related to specific medications included in each of
these categories. The study period for capturing
trends in opioid-related overdoses and poisoning
event rates is February 1, 2003 through July 1, 2013.
Trends in opioid-related overdoses and poisoning
rates are estimated for each 6-month interval.
State death data
State death data (ICD-10 codes for underlying cause of
death, contributory cause of death, and immediate cause
of death) are transferred to each site, incorporated into
the site’s data warehouse (harmonized across sites) using
a matching algorithm to identify health plan members,
and linked to electronic medical records and administra-
tive data for use in analyses. Only data from health plan
members are retained. All death data are available for
the full study period for KPNW members, though only
underlying cause of death is available for the full study
period for the KPNC membership. Therefore, we include
only underlying cause of death in primary analyses. It is
possible that deaths outside the relevant states may be
missed, but believe this to be a negligible problem.
Descriptive information
Demographic information available through administra-
tive systems will be collected, including age, gender,
race/ethnicity, Medicaid insurance, Medicare insurance.
Diagnostic data for the year preceding overdose or
poisoning events will also be collected for descriptive
purposes (e.g., history of substance use disorders; history
of psychiatric disorders).
Table 1 ICD poisoning codes used to identify overdosesa
ICD 9 code ICD 10 code
Poisoning by opium (alkaloids) unspecified 965.00
Poisoning by heroin 965.01
Poisoning by methadone 965.02
Poisoning by other opiates and related
narcotics
965.09
Accidental poisoning by heroin E850.0
Accidental poisoning by methadone E850.1
Accidental poisoning by other opiates
and related narcotics
E850.2
COD: Poisoning by opiates and related
narcotics
9650b
COD: Poisoning by opium T40.0
COD: Poisoning by heroin T40.1
COD: Poisoning by other opioids T40.2
COD: Poisoning by methadone T40.3
COD: Poisoning by other synthetic narcotic T40.4
COD: Accidental poisoning by and
exposure to narcotics and psychodysleptics,
not elsewhere classified
X42
COD: Intentional self-poisoning by and
exposure to narcotics and psychodysleptics,
not elsewhere classified
X62
COD: Undetermined poisoning by and
exposure to narcotics and psychodysleptics,
not elsewhere classified
Y12
aCase definition is met when a person has any diagnostic code from the
Case 1 list
bFor the year of 1998 only; COD codes changed to ICD 10 in 1999; ICD 9 codes
used for death data during 1998 did not include the fifth digit, which is why this
particular code is four digits and without a decimal
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Aim 1: data collection for opioid-related overdoses and
poisoning event validation
To assess the validity of using EMR diagnoses to accur-
ately identify and categorize opioid-related overdoses and
poisoning events, chart audits are conducted with a subset
of identified opioid-related overdoses and poisoning
events (Aim 1). Audits are conducted for the 2 years prior
to the introduction of the reformulated OxyContin® and
the 2 years following its introduction (August 1, 2008
through July 31, 2012). Provided with health record num-
bers, event dates, and inclusion diagnoses, chart auditors
review the EMR to locate the identified event for each per-
son and then compile all associated records for that event.
Records used may include history and physical records,
discharge summary, medication activity report, telephone
encounters, and any other related documentation. All
printed material and forms are kept in confidential, locked
files at all times when not in use.
Staff training begins with a sample of events reviewed
by all chart audit staff, adjudicators, and project investi-
gators at both sites to identify any issues with the chart
audit form, clarify questions, and ensure consistency in
review. A weekly teleconference call with chart audit
staff, investigators, expert adjudicators, and administra-
tive staff is held to identify and resolve questions related
to the events and the chart audit process. At each site,
200 of the first sample of charts are adjudicated by se-
nior research staff. Once the chart review form and asso-
ciated instructions are finalized, abstractors work on
individualized opioid-related overdoses and poisoning
event lists. Biweekly teleconferences are convened for
chart audit staff to discuss and resolve individual cases
and to refine definitions and instructions as needed.
The chart audit form is completed by auditors to
document the causal opioid(s), additional contributing
medication(s), contributing alcohol or illicit drug use,
Table 2 Opioid adverse effect codes used in combination with related diagnostic codes used to identify overdoses. To meet criteria,
a case had to include one diagnosis from category A and one more diagnoses from category B on the same date
Diagnostic category Diagnosis ICD 9 code ICD 10 code HCPCS code
A Adverse effects of heroin E935.0
A Adverse effects of methadone E935.1
A Adverse effects of other opioids and related narcotics E935.2
A COD: Adverse effects of opioids and related analgesics Y45.0
B Mixed acid–base balance disorder 276.4
B Drug-induced psychotic disordersa 292.1
B Drug-induced delirium 292.81
B Drug-induced mental disorderb 292.8
B Pneumonia, organism unspecified 486
B Chronic airway obstruction, not elsewhere classified 496
B Acute respiratory failure 518.81
B Other pulmonary insufficiency, not elsewhere classified 518.82
B Rhabdomyolysis 728.88
B Alteration of consciousness 780.0
B Altered mental state 780.97
B Apnea 786.03
B Shortness of breath 786.05
B Dyspnea and respiratory abnormalities—other 786.09
B Painful respiration 786.52
B Asphyxia and hypoxemia 799.0
B Poisoning by opiate antagonists 970.1
B Suicide and self-inflicted injury E950–E959
B Assault by drugs and medicinal substances E962.0
B Injection, Naloxone Hydrochloride J2310
aIncluding 292.11 and 292.12
bExcluding 292.81
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prescription detail (dose and frequency), route of admin-
istration for each substance, source of each substance
when available (e.g., prescription, friend, family member,
Internet, street, etc.), and any indication of misuse,
abuse, or over-administration for each substance. Audi-
tors also use the form to record administration and re-
sponse to naloxone hydrochloride and whether the event
is solely related to anesthesia administered for a proced-
ure. Events solely related to anesthesia are not abstracted
further.
Chart auditors use a study-designed medication
codebook to document all substances related to the
identified opioid-related overdoses and poisoning event.
This codebook lists all opioids in each comparator
group, prescription medications verified to have
moderate or severe interactions with opioids, and over-
the-counter medications known to interact with opioids
as well as alcohol and illicit substances. The codebook
includes 1355 medications and substances and is used to
identify all medications and substances involved or
potentially involved in each opioid-related overdose and
poisoning event. Following each review, chart auditors
summarize the findings as follows:
1) The extent to which substances are involved with
the event (only one option is selected)
a. Not an opioid event (no mention of opioids).
b. Single opioid event (only one opiate is involved in
the event; no other medications or other
substances likely contribute, per documentation).
c. Poly-substance opioid event (at least one substance
in addition to an opioid likely or possibly
contributes to the event, per documentation).
d. Event unrelated to opioid use (there is a mention
of opioids at the time of the event but opioids
did not contribute to the event).
2) Whether the event appears to be one of the
following (only one option is selected):
a. Miscode (diagnostic code or codes that appear to
have been applied in error, or documentation of
event that does not match the codes applied to
that event).
b. Misidentification (diagnostic code or codes and
medication are both correct but are not related to
each other and not of interest to the study).
c. Neither of the above (documentation in chart is
consistent with the EMR-based identification of
the event).
When an event is deemed to be miscoded or misidenti-
fied, the audit is stopped and the event is sent to an expert
adjudicator for confirmation and further documentation
regarding the specifics of the miscode or misidentification
determination. This information is logged separately from
the audit form. These data are compiled and are analyzed
separately to look for patterns in inconsistently or incor-
rectly applied ICD codes within the EMR system.
For all events determined to be consistent with EMR-
based identifications as opioid-related overdoses and
poisoning or opioid-related adverse effects, data collec-
tion staff then determine the type of event (only one op-
tion is selected):
a. Intentional opioid-related overdose or and poisoning
(EMR records are clear that the event was
intentional [e.g., suicide or attempt] and involved
opioids [single-opioid or poly-drug]).
b. Unintentional opioid-related overdoses or poisoning
(EMR records are clear that the event was not
intentional [e.g., trying to get high; medication error]
and involved opioids [single-opioid or poly-drug]).
c. Adverse effect related to opioid use (event related o
opioid use but did not require intervention beyond
adjusting or discontinuing medication for
resolution). Sensitivities to properly administered
medications are coded here unless they require
additional intervention to resolve symptoms.
For events that have no EMR information available on
the provided date, outside claims data from both sites
are reviewed by senior research staff to provide an
Table 3 Classification structure for specific medications
included in opioid medication hierarchy
Category Group Generic name
1 OxyContin® n/a
Oxycodone SISR oxycodone SR
2 Oxycodone SIIR oxycodone
















aIncludes all codeine and hydrocodone combination products
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indication of intentionality or number of substances
involved in the event. These cases are visits and treat-
ments provided at non-KPNW or non-KPNC facilities
(e.g., ambulance transport for overdose to the nearest
hospital). Determinations made from outside claims data
are confirmed with clinical staff and the study PI accord-
ing to the following criteria:
a. Intentional vs unintentional: If coding documents
any indication of suicide (e.g., attempt, ideation,
self-inflicted) the event is determined to be
“intentional”. If there is no such mention, the event
is coded “unintentional”.
b. Single vs poly-drug: If there is an indication of more
than one substance based on outside claims coding
(e.g., alcohol intoxication and accidental opiate
poisoning) the event is coded “poly-drug”. If only one
substance is recorded as poisoning (e.g., methadone
poisoning) the event is coded “single”. If only one
substance is recorded but additional opiate poisoning
or abuse codes are also applied (e.g., heroin poisoning
and opioid abuse) the event is coded “single”.
c. If there is no information in the claims data related
to opioid use, the event is coded as “not an
opioid event”.
Each audit file is reviewed for missing data prior to
data entry; if forms are incomplete, the file is returned
to the staff person who collected the data for com-
pletion. Ten percent of charts are reviewed by two re-
viewers to assess and maintain high inter-rater reliability
(>95 %). All identified errors are discussed and cor-
rected. Once abstraction files are complete, data are
entered into an electronic database using double entry
verification until adequate accuracy is obtained (less
than 1 error/100 entries). Once this level is achieved,
10 % of data are double-entered as a continuous check.
Following entry, data files from both sites are merged
for analysis.
Aim 4: qualitative data collection
To understand the circumstances surrounding opioid-
related overdoses and poisoning events, we conduct in-
depth interviews with a subset of patients who
experience an opioid-related overdoses and poisoning
event. We also conduct interviews with family members
of patients who died as a result of an opioid-related
overdoses and poisoning event.
Interview candidates (n = 90) are identified from the
sample of KPNW member with identified opioid-related
overdoses or poisoning events. Family members are
identified using subscriber account information linked to
the decedent’s EMR information, when such information
is available.
We sample randomly from purposefully derived pools
of people with and without active prescriptions for opi-
oids and oversampling within key subgroups. Pharmacy
records are reviewed to determine whether a person
with an opioid-related overdose and poisoning event had
an active opioid prescription at the time of the event.
Because numbers of OxyContin®-associated events are
small, we oversample members with active OxyContin®
or sustained release oxycodone prescriptions at the time
of the event. We also oversample members with no ac-
tive opioid prescription (no opioid group) in order to
identify people engaged in non-medical use of opioids.
Members with events in the remaining three comparator
groups (oxycodone SIIR, other class REMS, and other
opioid) are sampled proportionally based on the number
of total opioid-related overdoses and poisoning events
identified in each of those categories. We also attempt
to balance our sample to obtain roughly equal numbers
of male and female participants in each of the opioid
categories.
Recruitment
Potential participants are recruited using mailed letters
with follow-up telephone calls inviting participation in a
one-time interview and promising compensation of $50.
For deceased health plan members whose medical re-
cords indicate that opioid overdose was the cause of
death and who have no other members associated with
their subscriber unit, we mail a letter to the deceased
member’s most recent address.
To improve recall regarding the circumstances sur-
rounding opioid-related overdoses and poisoning events,
interview candidates are identified from the opioid-
related overdose and poisoning event sample from the
6 months prior to the introduction of OxyContin® with
abuse-deterrent properties through the years following
the introduction. Individuals with more than one active
opioid prescription at the time of the opioid-related
overdoses and poisoning event (e.g., a sustained-release
formulation and an immediate-release formulation for
breakthrough pain) are sampled based on their cate-
gorization into their “highest” medication comparator
group in the hierarchy.
Interviews
The purpose of the qualitative interviews is to gain further
insight into patients’ experiences of overdoses and poison-
ing events; with family members the goal is to understand
as much as possible about the decedent’s experiences prior
to overdose. Interviews with patients are semi-structured
and focus on pain history, initiation of analgesic medica-
tions, switches in prescribed opioid medications or change
in dose, misuse of opioids or other prescription medica-
tions, illegal drug use and abuse history, the circumstances
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leading up to and culminating in the specific overdose or
poisoning event identified through the EMR, and any post-
event treatment plans, medication changes or changes in
drug use activity. Because many people experience more
than one opioid-related overdose and poisoning event,
those additional events may also be explored. We also ask
about the opioids individuals were taking, other prescribed
medications at the time of the events, contributing alcohol
or illicit drug use, prescription details (dose and fre-
quency), route of administration for each substance, and
source of each substance (e.g., prescription, friend, family
member, Internet, street, etc.). Interviewers also explore
indicators of of misuse, abuse, or over-administration for
each substance as well as mental health status. Interviews
with family members focus on similar questions.
Interviews are conducted using a semi-structured
interview guide (see Additional files 1 & 2) to ensure
similar questions are asked of all participants. Additional
prompts and questions are added during individual in-
terviews to further explore important information.
Experienced master’s- and doctoral-level staff mem-
bers conduct these hour-long interviews. Participants
consent to participate in the interview portion of the
study and are provided a copy of their signed consent
form and a $50 gift card to a local supermarket chain
upon interview completion.
Data analysis
Aim 1 analyses: assess the validity of ICD-9 and ICD-10
diagnoses to accurately identify and categorize opioid-
related overdoses and poisonings using chart audits
Opioid-related overdoses and poisoning events are identi-
fied and then compared to chart audits using the following
approach: We use individual and combined ICD-9 and
ICD-10 codes from the KP Virtual Data Warehouse
(VDW), linked to state death data. The VDW, contains
comparable data across multiple participating sites, in-
cluding KPNW and KPNC, for the conduct of research,
including enrollment, demographics, tumor registries,
pharmacy dispenses, census data, vital signs, and diagno-
ses and procedures. We then calculate positive predictive
value of EMR-based diagnostic codes compared to chart
audit determinations and describe final chart audit deter-
minations and categorizations for each code. Overdoses
are also described using chart audit-based categorizations
(e.g., suicide event or attempt; polydrug event).
Aim 2 analyses: estimate rates of, and compare trends in,
opioid-related overdoses before and after the introduction
of OxyContin® with abuse-deterrent properties, among
patients with and without active opioid prescriptions, and
those involving heroin
For Aim 2, we compare trends in rates of opioid-related
overdoses and poisoning events associated with OxyContin®
to rates of opioid-related overdoses and poisoning events
associated with other oxycodone and opioid formulations
over a 10-year period (February 1, 2003-July 30, 2013).
Rates are computed in 6-month intervals from the 7 years
prior to the reformulation of OxyContin® and through the
3 years following the introduction of the new formulation.
These rates are graphed over time for each category of
opioid (immediate-release single ingredient oxycodone,
other long-acting opioids for which the FDA has required
REMS, and other Schedule II opioids), and well as over-
doses among individuals with no active opioid prescrip-
tions to compare trends across all categories. Prior to
2005, all extended-release (ER) oxycodone distributed in
the marketplace was branded OxyContin®. In 2005, several
generic manufacturers challenged the patent for branded
OxyContin® and began to sell generic extended-release
oxycodone. The proportion of branded ER oxycodone
(OxyContin®) versus generic ER oxycodone declined rap-
idly. The manufacturer of OxyContin®, Purdue Pharma,
L.P., won the patent back in January 2008 and the propor-
tion of branded versus generic ER oxycodone rapidly in-
creased to approximately 85 % of ER oxycodone used in
the U.S. To address these changes in the marketplace, the
rates of overdose and poisoning in the period prior to the
introduction of the new formulation are calculated separ-
ately for branded and generic ER oxycodone. If similar,
they will be combined and used as the pre-introduction
rates, then compared to the post-introduction rates for
branded ER oxycodone.
Calculation of rates
Poisonings and overdoses related to opioids are the
opioid-related events of interest. Dependent variables
are the rates of these events in 6-month intervals. We
compute rates in two ways. First, we compute the rate of
events per number of people with a dispense in each cat-
egory. For example:
Number of poisonings=overdoses for people with a dispense of OxyContinW
oxycodone SR
Number of people with a dispense of OxyContinW=oxycodone SR
Second, we compute the rate per total morphine
equivalent in milligrams by category (but including all
prescribed opioids). For example:
Number of poisonings=overdoses for people with a dispense of OxyContinW
oxycodone SR
Morphine equivalent milligrams of all dispenses of OxyContinW=oxycodone SR
Rates will be computed for each 6-month period for
immediate-release single-ingredient oxycodone, other
class REMS opioids, and other Schedule II opioids. These
two types of rate calculations are used as dependent vari-
ables to assess changes in rates of opioid-related overdoses
and poisoning events following introduction of the new
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formulation and to assess secular trends in rates by com-
paring to the other opioid groups.
Aim 3 analyses: compare the ratio of rates of opioid-related
overdoses and poisoning events among patients prescribed
and dispensed OxyContin® with rates in comparator opioid
groups, 2 years prior to and 2 years following the
introduction of the new formulation of OxyContin®
For the rate ratio analysis for Aim 3, we examine over-
dose and poisoning rates calculated by dividing the
number of events by the total number of person-years
during pre-reformulation and post-reformulation time
periods. Negative binomial regression analysis will be
used to compare rates between the pre- and post- time
periods. Because the same health plan members can
appear both in time periods, a generalized estimating
equations (GEE) approach is used to account for the
correlated nature of the data. Rate ratios analysis exam-
ining change from pre- to post- reformulation will be
conducted for each opioid category and heroin overdose
events, per 10,000 person years. All persons in the health
plans will be included in these analyses regardless of
whether or not they were currently prescribed an opioid.
Statistical power
Initial power estimates are based on detecting a change in
the rate of overdose/poisoning events after the new for-
mulation of OxyContin among patients with dispenses of
OxyContin, as this is the smallest group to be included in
analyses. We estimated the number of patients needed to
detect various effect sizes when the rate for the two years
prior to the new formulation is compared to the rate for
the first year following the new formulation (see Table 4).
Pilot data in Kaiser Permanente Northwest indicated that
approximately 1 % of patients taking OxyContin experi-
enced an overdose with the old formulation. Data form
KPNW and KPNC estimates 6711 patients with active
prescriptions of OxyContin in a 6-month window. Table 3
summarizes the number of patients with a dispense of
OxyContin needed to detect various effect sizes or
changes in the rate of overdose events after the introduc-
tion of the new formulation.
Aim 4: qualitative data analysis
Interviews are audio-recorded and transcribed verbatim.
Study investigators and interviewers review transcripts
weekly throughout data collection to ensure transcript ac-
curacy and appropriate interviewing techniques. Coding
schemes for the patient interviews and family member in-
terviews are developed separately. Senior research staff
use Atlas.ti software [27] to systematically apply codes to
interview transcripts. We complete check coding through-
out the process to ensure coder consistency; inconsisten-
cies are discussed and resolved by the team, and code
definitions revised as needed. We anticipate a coder
consistency of at least 80 %, and will work to resolve dis-
crepancies, rework code definitions, and retrain coders if
this is not achieved. Once data are coded, we generate
theme reports following review of code-based queries.
Themes are compared within codes and across codes, and
text selected to illustrate common themes. Contradictory
text is also identified and collected for inclusion in reports.
Interview data are then linked to EMR and chart abstrac-
tion data, triangulated and compared.
Discussion
This study is designed to assess and track changes in
opioid-related overdoses and poisoning events prior to
and following the introduction of OxyContin® with
abuse-deterrent properties. The main goals of the study
are to 1) identify and assess trends in opioid-related
overdoses and poisoning events during the full study
period, 2) verify and validate opioid-related overdoses and
poisoning events using chart audits, and 3) understand,
from the patient’s or family member’s perspectives, the cir-
cumstances surrounding opioid-related overdoses and
poisoning events. Findings from this study will be signifi-
cant for several reasons: First, we will be able to assess the
effects of OxyContin® with abuse-deterrent properties on
overdose and poisoning events. Second, the study will pro-
duce validated methods of identifying opioid-related over-
doses and poisoning events that can be used for public
health surveillance. Third, we will have documented first-
person accounts of the circumstances surrounding and
leading up to opioid-related overdoses and poisoning
events, and the effects of abuse-deterrent properties on
the behaviors of individuals with such events.
Strengths and limitations
Strengths of the study included the comprehensive data
available through electronic medical records that are linked
to health plan administrative and claims data, pharmacy
dispenses, and state death records. In addition, chart audits
and interviews provide in-depth data that aid understand-
ing of overdose events and circumstances surrounding
overdoses. Chart audits will provide an assessment of the
validity of using diagnostic codes for identifying overdoses
and poisonings. Limitations of the study include that it will
be carried out in insured populations, although the health
plans’ populations are demographically representative of
Table 4 Sample size needed to detect various effect sizes
Reduction in rate of overdose/
poisoning events
80 % power 90 % power
25 % 16,617 22,239
50 % 3635 4865
75 % 1378 1845
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the populations in the geographic areas they serve and in-
formation about overdose in insured populations is also
lacking. The health plans are likely, however, to underre-
present individuals in the poorest strata and also those
with substance use disorders that would negatively affect
ability to obtain or maintain insurance. Death data may be
incomplete if individuals do not die in the states of
Oregon, Washington, or California, where participating
health plans are located. This limitation is expected to be
negligible.
Implications for practice
Opioid abuse, dependence, and overdose ruin peoples’
lives, and societal costs are substantial, including lost
productivity, increased healthcare costs, and greater
criminal justice involvement and costs [9]. Reducing the
likelihood of opioid-related overdoses and poisoning
events can help both individuals and overall population
health. The results of this study will inform clinicians
about the effects of adopting opioid medications with
abuse-deterrent properties for chronic pain treatment.
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